Trials / Conditions / Impaired Hepatic Function

Impaired Hepatic Function

8 registered clinical trials studyying Impaired Hepatic Function.

Status	Trial	Sponsor	Phase
Terminated	Study of ALXN2050 in Participants With Hepatic Impairment NCT05259085	Alexion Pharmaceuticals, Inc.	Phase 1
Completed	Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function NCT04823702	NGM Biopharmaceuticals, Inc	Phase 1
Terminated	A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic NCT04136444	UCB Biopharma S.P.R.L.	Phase 1
Completed	Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011 NCT02388620	Novartis Pharmaceuticals	Phase 1
Completed	Effect of Hepatic Impairment on LDK378 Pharmacokinetics NCT01950481	Novartis Pharmaceuticals	Phase 1
Completed	A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impair NCT02135302	Tetraphase Pharmaceuticals, Inc	Phase 1
Completed	Effect of Hepatic Impairment on LDE225.. NCT01764776	Novartis Pharmaceuticals	Phase 1
Completed	Evaluating Patients With Impaired Hepatic Function NCT00398424	Taiho Oncology, Inc.	Phase 1